Montanova Capital LLC Increases Position in Capricor Therapeutics, Inc. $CAPR

Montanova Capital LLC lifted its position in shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR) by 7.2% during the second quarter, Holdings Channel reports. The institutional investor owned 4,092,784 shares of the biotechnology company’s stock after purchasing an additional 274,184 shares during the period. Capricor Therapeutics makes up approximately 1.6% of Montanova Capital LLC’s investment portfolio, making the stock its 19th biggest position. Montanova Capital LLC owned about 0.07% of Capricor Therapeutics worth $98,554,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Suvretta Capital Management LLC bought a new position in shares of Capricor Therapeutics in the fourth quarter worth about $51,533,000. Tang Capital Management LLC purchased a new position in Capricor Therapeutics in the 4th quarter worth approximately $49,062,000. RA Capital Management L.P. purchased a new position in Capricor Therapeutics in the 4th quarter worth approximately $43,516,000. Darwin Global Management Ltd. bought a new position in Capricor Therapeutics in the 4th quarter worth approximately $23,168,000. Finally, SB Capital Management Inc bought a new position in Capricor Therapeutics in the 4th quarter worth approximately $11,544,000. Institutional investors own 21.68% of the company’s stock.

Insiders Place Their Bets

In related news, CFO Anthony Bergmann sold 24,100 shares of the firm’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $30.38, for a total value of $732,158.00. Following the transaction, the chief financial officer owned 11,223 shares of the company’s stock, valued at $340,954.74. This trade represents a 68.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders sold a total of 25,000 shares of company stock valued at $759,158 in the last 90 days. Company insiders own 9.20% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Cantor Fitzgerald upgraded shares of Capricor Therapeutics from a “neutral” rating to an “overweight” rating in a research report on Friday, August 14th. Roth Capital lowered shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 target price for the company. in a research report on Monday, July 27th. HC Wainwright reiterated a “neutral” rating on shares of Capricor Therapeutics in a report on Monday, July 27th. Oppenheimer upgraded shares of Capricor Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, August 25th. Finally, Maxim Group cut Capricor Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, July 30th. Two research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $29.15.

Key Headlines Impacting Capricor Therapeutics

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: The FDA has extended its review of Capricor’s Biologics License Application for deramiocel, meaning the application remains under regulatory consideration. Hagens Berman FDA review extension alert
• Neutral Sentiment: Multiple law firms reiterated that investors who purchased CAPR securities from December 17, 2025, through July 26, 2026, have until September 28, 2026, to seek appointment as lead plaintiff in the pending class action. These announcements repeat the same deadline and do not represent new court findings or a determination of liability. Robbins Geller Capricor investor deadline notice
• Negative Sentiment: The securities lawsuit alleges that Capricor misled investors about the progress of deramiocel’s application toward the August 22, 2026 PDUFA date by allegedly failing to disclose that the final statistical analysis plan for the HOPE-3 study had not been submitted to or agreed upon by the FDA before the application was resubmitted. The allegations and related regulatory scrutiny create legal, reputational, and approval risks for CAPR. Levi and Korsinsky Capricor shareholder alert
• Negative Sentiment: A series of investor-law-firm announcements highlighted the pending fraud case and referenced a prior sharp selloff following clinical-data and regulatory disclosures. The repetition of these notices keeps the litigation overhang prominent and may weigh on sentiment even as the FDA review continues. BFA Law Capricor investment losses alert

Capricor Therapeutics Stock Up 3.3%

Shares of CAPR opened at $9.91 on Tuesday. The business has a fifty day moving average of $14.07 and a 200 day moving average of $24.19. The company has a market cap of $576.17 million, a PE ratio of -4.04 and a beta of 0.54. Capricor Therapeutics, Inc. has a 52-week low of $2.96 and a 52-week high of $40.37.

Capricor Therapeutics (NASDAQ:CAPR) last released its earnings results on Thursday, August 13th. The biotechnology company reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.11). As a group, research analysts anticipate that Capricor Therapeutics, Inc. will post -1.72 earnings per share for the current fiscal year.

Capricor Therapeutics Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.